

CONTENTS

Preface	v
Contributors	xi
Color Illustrations	xv
I CANCER DRUG DEVELOPMENT	
1 Cancer Drug Development: <i>Challenges in a Competitive Market</i> <i>Barry Greene and Michael Kauffman</i>	3
II CHEMISTRY AND CELL BIOLOGY OF THE PROTEASOME	
2 Introduction to the Proteasome and Its Inhibitors: <i>Biochemistry and Cell Biology</i> <i>Alfred L. Goldberg</i>	17
3 Structures of the Yeast Proteasome Core Particle in Complex with Inhibitors <i>Michael Groll and Robert Huber</i>	39
4 Natural Product and Synthetic Proteasome Inhibitors <i>Kyung Bo Kim and Craig M. Crews</i>	47
5 Other Proteasome Inhibitors <i>Carlos García-Echeverría</i>	65
6 The Proteasome in Cell-Cycle Regulation <i>Julian Adams</i>	77
7 Proteasome Inhibition and Apoptosis <i>Simon A. Williams and David J. McConkey</i>	85
8 The Proteasome and the COMPARE Algorithm <i>Susan L. Holbeck and Edward A. Sausville</i>	99
III RATIONALE FOR PROTEASOME INHIBITORS IN CANCER	
9 The Proteasome in Cancer Biology and Therapy <i>Frank Pajonk and William H. McBride</i>	111
10 Radiosensitization and Proteasome Inhibition <i>Carter Van Waes, John B. Sunwoo, William DeGraff,</i> <i>and James B. Mitchell</i>	123
11 Proteasome-Dependent Regulation of NF- κ B Activation: <i>Molecular Targeting of Chemotherapy Resistance</i> <i>James C. Cusack, Jr.</i>	131
12 Bortezomib with Taxanes <i>Leonard Liebes, Bruce Ng, Yi-He Ling, and Roman Perez-Soler</i>	145
13 Proteasome Inhibitor Therapy in a Brain Tumor Model <i>Jeffrey J. Olson, Geoffrey Bowers, and Zhaobin Zhang</i>	161
14 Anthracyclines and Bortezomib <i>Robert Z. Orlowski</i>	171

15	TNF-Related Apoptosis-Inducing Ligand (TRAIL): <i>Combination with Proteasome Inhibition For Anticancer Therapy?</i> Thomas J. Sayers	181
16	Rationale for Combining the Proteasome Inhibitor Bortezomib with Cisplatin Edward G. Mimnaugh and Leonard M. Neckers	193
17	The Effects of the HIV-1 Protease Inhibitor Ritonavir on Proteasome Activity and Antigen Presentation Marcus Groettrup, Rita de Giuli, and Gunter Schmidtke	207
18	Function(s) of the Ubiquitin–Proteasome System in Retrovirus Budding Ulrich Schubert	217
IV CLINICAL TRIALS		
19	Preclinical Development of Bortezomib (VELCADE™): <i>Rationale for Clinical Studies</i> Julian Adams, Peter J. Elliott, and Page Bouchard	233
20	Phase I Trials: <i>Bortezomib Alone and in Combination</i> <i>With Standard Chemotherapies</i> Dixie-Lee W. Esseltine and David P. Schenkein	271
21	Clinical Molecular Diagnostics for Proteasome Inhibitors in Cancer Therapy Jeffrey S. Ross, Gerald P. Linette, Geoffrey S. Ginsburg, William Trepicchio, Oscar Kashala, Rebecca Mosher, Jeffrey Brown, George Mulligan, Jim Deeds, and James Stec	283
22	Phase II Trials of Bortezomib for the Treatment of Multiple Myeloma Kenneth C. Anderson	301
	Index	307



<http://www.springer.com/978-1-58829-250-6>

Proteasome Inhibitors in Cancer Therapy

Adams, J. (Ed.)

2004, XV, 313 p., Hardcover

ISBN: 978-1-58829-250-6

A product of Humana Press